Jeong Nam Soo

Dr. Jeong Nam Soo

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2020 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
JSJeong Nam Soo
Jeong Nam Soo
Yosep ChongYosep Chong
Yosep Chong
Chan Kwon JungChan Kwon Jung
Chan Kwon Jung
TKTae-Yeong Kwak
Tae-Yeong Kwak
JLJi Youl Lee
Ji Youl Lee
HGHeounjeong Go
Heounjeong Go
Digital pathology (DP) is no longer an unfamiliar term for pathologists, but it is still difficult for many pathologists to understand the engineering and mathematics concepts involved in DP. Computer-aided pathology (CAP) aids pathologists in diagnosis. However, some consider CAP a threat to the existence of pathologists and are skeptical of its clinical utility. Implementation of DP is very burdensome for pathologists because technical factors, impact on workflow, and information technology infrastructure must be considered. In this paper, various terms related to DP and computer-aided pathologic diagnosis are defined, current applications of DP are discussed, and various issues related to implementation of DP are outlined. The development of computer-aided pathologic diagnostic tools and their limitations are also discussed.

25 May 2022 in Medical Image Analysis
Verified
Journal Article
Closed access
PCPHILIP CHIKONTWE
PHILIP CHIKONTWE
HSHyun Jung Sung
Hyun Jung Sung
JJJaehoon Jeong
Jaehoon Jeong
MKMeejeong Kim
Meejeong Kim
HGHeounjeong Go
Heounjeong Go
Sang Hyun ParkSang Hyun Park
Sang Hyun Park

27 November 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
JSJeong Nam Soo
Jeong Nam Soo
YKYoung-Hoon Kim
Young-Hoon Kim
JPJi Eun Park
Ji Eun Park
YRYoung-Shin Ra
Young-Shin Ra
SKShin Kwang Khang
Shin Kwang Khang
CSChang Ohk Sung
Chang Ohk Sung

1 March 2022 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
SKSae Min Min Kwon
Sae Min Min Kwon
JKJeong Hoon Kim
Jeong Hoon Kim
YKYoung-Hoon Kim
Young-Hoon Kim
SHSeok Ho Hong
Seok Ho Hong
YCYoung Hyun Cho
Young Hyun Cho
JSJeong Nam Soo
Jeong Nam Soo
Objective : Intracranial atypical meningiomas have a poor prognosis and high rates of recurrence. Moreover, up to one-third of the recurrences undergo high-grade transformation into malignant meningiomas. We aimed to investigate the clinical factors that can predict the propensity of malignant transformation from atypical to anaplastic meningiomas.Methods : Between 2001 and 2018, all patients with atypical meningioma, in whom the tumors had undergone malignant transformation to anaplastic meningioma, were included. The patients’ medical records documenting the diagnosis of atypical meningioma prior to malignant transformation were reviewed to identify the predictors of transformation. The control group comprised 56 patients with atypical meningiomas who were first diagnosed between January 2017 and December 2018 and had no malignant transformation.Results : Nine patients in whom the atypical meningiomas underwent malignant transformation were included. The median time interval from diagnosis of atypical meningioma to malignant transformation was 19 months (range, 7–78). The study group showed a significant difference in heterogeneous enhancement (77.8% vs. 33.9%), bone invasion (55.6% vs. 12.5%), mitotic index (MI; 14.8±4.9 vs. 3.5±3.9), and Ki-67 index (20.7±13.9 vs. 9.5±7.1) compared with the control group. In multivariate analysis, increased MI (odds ratio, 1.436; 95% confidence interval, 1.127–1.900; p=0.004) was the only significant factor for predicting malignant transformation.Conclusion : An increased MI within atypical meningiomas might be used as a predictor of malignant transformation. Tumors at high risk for malignant transformation might require more attentive surveillance and management than other atypical meningiomas.

1 November 2021 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
DSDong-Won Shin
Dong-Won Shin
JKJeong Hoon Kim
Jeong Hoon Kim
SSSang Woo Song
Sang Woo Song
YKYoung-Hoon Kim
Young-Hoon Kim
YCYoung Hyun Cho
Young Hyun Cho
JSJeong Nam Soo
Jeong Nam Soo
Objective : The occurrence of posterior fossa teratomas in adulthood is extremely rare. In this study, we aimed to report our experience with two cases of posterior fossa mature teratoma in adults who underwent surgical resection. We also performed a systematic review of published papers available to date.Methods : We retrospectively reviewed the electronic medical records of patients who had onset of posterior fossa teratomas in adulthood at our institute between 1995 and 2020. We evaluated the clinical, radiographic, and pathological features of mature teratomas at the posterior fossa in adulthood. Furthermore, we searched the PubMed, EMBASE, and Web of Science database and reviewed published articles.Results : We found 507 articles on database review; of them, 102 were duplicates and 389 were excluded based on the inclusion criteria. Finally, 16 cases of posterior fossa from the web search and related articles. Subsequently, we added two cases that underwent surgery at our institute. We analyzed a total of 18 cases of mature teratomas. Headache was the most common (55.6%) symptom. The teratomas showed heterogeneous signals on magnetic resonance imaging. Thirteen patients (72.2%) had lesion at midline, five patients (27.8%) had calcification. Surgical resection was performed in all patients. No studies reported recurrence after resection.Conclusion : The occurrence of posterior fossa teratomas in adulthood is difficult to diagnose at the initial stage. Radiographic diagnosis alone can lead to misdiagnosis. Pathological confirmation is essential. Surgical resection is a curative option for posterior fossa teratomas in adulthood.

15 July 2024 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
MKMiso Kim
Miso Kim
HSHyo Sup Shim
Hyo Sup Shim
SKSheehyun Kim
Sheehyun Kim
ILIn hee Lee
In hee Lee
JKJihun Kim
Jihun Kim
WKWan Seop Kim
Wan Seop Kim
In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.